Abstract
In this study, the enrolled patients were treated with active glucose control, blood pressure control or improvement of anemia. And instruct patients to adhere to low-salt and low-fat diet, ingest part of a low-protein diet, and reduce the effect of glomerular hyperfiltration as much as possible. When the disease enters the third stage, the doctor usually recommends a protein intake of 0.6 g/(kg d) to slow down the progression of the disease as much as possible. From the perspective of traditional Chinese medicine, according to the existing theory, CKD is more common, and its treatment principle is mainly to strengthen the spleen and kidneys, eliminate pathogenic bacteria, and activate meridians. The results of this study showed that serum creatinine and blood urea nitrogen levels in the traditional Chinese medicine group were lower than those in the conventional group. The overall effective rate of the TCM group was 73.33%, which was much higher than that of the conventional group. Traditional Chinese medicine to strengthen renal function and digging method has good efficacy in patients with stage 3–4 chronic kidney disease and has high application value in promoting the recovery of biochemical indexes, alleviating clinical symptoms and adverse drug reactions.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
Data will be made available on request.
References
Dubey AK, Sahoo J, Vairappan B, Parameswaran S, Priyamvada PS (2021) Prevalence and determinants of sarcopenia in Indian patients with chronic kidney disease stage 3 & 4. Osteoporos Sarcopenia 7(4):153–158
Fraser SD, Roderick PJ, May CR, McIntyre N, McIntyre C, Fluck RJ, Taal MW (2020) Correction to: The burden of comorbidity in people with chronic kidney disease stage 3: a cohort study. BMC Nephrol 21:1–11
Kitamura M, Arai H, Abe S, Ota Y, Muta K, Furusu A, Nishino T (2020) Renal outcomes of treatment with telmisartan in patients with stage 3–4 chronic kidney disease: a prospective, randomized, controlled trial (JINNAGA). SAGE Open Medicine 8:2050312120973502
Kuo I, Lee JJ, Hwang DY, Lim LM, Lin HYH, Hwang SJ, Hung CC (2020) Pyuria, urinary tract infection and renal outcome in patients with chronic kidney disease stage 3–5. Sci Rep 10(1):1–9
Li N, Fan P (2021) Discussion on traditional chinese medicine understanding of renal cyst. J Clin Nurs Res 5(5):58–61
Li R, Song Z, You Q (2021) Current status of traditional chinese and western medicine treatment of diabetic peripheral vascular disease. Proc Anticancer Res 5(4):43–45
Li X, Liu W, Wang X, et al (2019) Advances in clinical research on prevention and treatment of diabetic nephropathy by Jingfang of promoting blood circulation and removing blood stasis. In: IOP conference series: materials science and engineering. IOP Publishing 677(3):032086
Li X, Zheng H, Zhou Z, Li Z, Zhou X, Zheng M (2022) Clinical effect of mudan granule on peripheral neuritis caused by chronic renal insufficiency. Comput Math Methods Med
Lu Z, Liu W, Gao H, Chen W, Ge W, Li F, Deng Y (2021) Traditional Chinese Medicine as an adjunct therapy in the treatment of idiopathic membranous nephropathy: a systematic review and meta-analysis. PLoS ONE 16(5):e0251131
Shankar PR, Davenport MS (2020) Risk of nephrogenic systemic fibrosis in stage 4 and 5 chronic kidney disease following group II gadolinium-based contrast agent administration: subanalysis by chronic kidney disease stage. Radiology 297(2):447–448
Shao-Ning D, Wang YG (2016) Explore the medication rules of Chinese medicine of Professor Huang Wenzheng for the treatment of chronic kidney disease based on data mining. Tradit Med Res 1(3):156
Wang X, Chen H (2014) Progress in the revision of the definition and staging system of chronic kidney disease: interpretation of the 2012-KDIGO clinical management practice guideline for chronic kidney disease. Chin J Mult Organ Dis Elder 5:396–400
Weidong L, Liuting C, Haiyang L, Jianhong P, Xueying Y (2022) Treatment of refractory acute gout by invigorating spleen, raising Yang, dehumidifying, and dredging collaterals: a metabolomics study. Pharmacol Res Mod Chin Med 3:100091. https://doi.org/10.1016/j.prmcm.2022.100091
Zemke AM, Rodby RA, Hertl M, Waleed A, Bakris GL (2022) Successful treatment of refractory hypertension with bilateral nephrectomy in a patient with chronic kidney disease stage 3. Clin Kidney J 15(2):347–350
Zhang WJ, Wang ZY, Zhou WX, Yang NQ, Wang Y, Tang Y, Yang L (2020) Identifying risk factors for chronic kidney disease stage 3 in adults with acquired solitary kidney from unilateral nephrectomy: a retrospective cohort study. BMC Nephrol 21:1–10
Zhao J, Sun W, Chen J, Sun Z, Chen D, Cao C, Zhu Y (2020) Efficacy and safety of Chinese herbal formula granules in treating chronic kidney disease stage 3: a multicenter, randomized, placebo-controlled, double-blind clinical trial. Evid Based Complement Altern Med. https://doi.org/10.1155/2020/4073901
Funding
This work was supported by the Geriatrics Society Geriatrics Science and Technology Development Fund Project of Jiangsu Province (JGS2019ZXYY019), Science and Technology Development Project of Suzhou (SYSD2019156; SKYXD2022060) and 2020 "National Tutor System" training project for Key Young health talents in Suzhou.
Author information
Authors and Affiliations
Contributions
YR and XD contributed equally and could be treated as co-first author. WS and CJ (719376715@qq.com) are co-corresponding author.
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interests.
Ethical approval
This article does not contain any studies with human participants performed by any of the authors.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Ren, Y., Duan, X., Ni, D. et al. Clinical evaluation of nano targeted delivery system based on Chinese medicine Yishen-Huoluofang components for chronic kidney disease stage 3–4. Soft Comput (2023). https://doi.org/10.1007/s00500-023-08901-7
Accepted:
Published:
DOI: https://doi.org/10.1007/s00500-023-08901-7